Taysha Gene Therapies Announces Multiple Presentations Highlighting its TSHA-102 Clinical Program at the 2026 IRSF Rett Syndrome Scientific Meeting
Taysha Gene Therapies announced multiple upcoming presentations of its TSHA-102 clinical trial data at the 2026 International Rett Syndrome Foundation scientific meeting. The data show broad, sustained functional improvements in Rett syndrome patients up to 12 months post-treatment across age groups and disease severity. New analyses support the us…